ENXTBR:ARGXBiotechs
Argenx Eyes Broader Autoimmune Reach After VYVGART Ocular MG Success
Argenx (ENXTBR:ARGX) reported positive topline Phase 3 ADAPT OCULUS results for VYVGART in adults with ocular myasthenia gravis.
The study met its primary endpoint with statistically significant efficacy in this patient group, which currently has limited treatment options.
The data are intended to support regulatory submissions that could extend the existing VYVGART label to include ocular myasthenia gravis.
Argenx is pairing these results with a broader push to expand VYVGART indications...